Toward a Single-Dose Cure for Buruli Ulcer
Sign Up to like & getrecommendations! Published in 2020 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00727-20
Abstract: A single dose of Q203 (Telacebec), a phase 2 clinical candidate for tuberculosis, eradicates Mycobacterium ulcerans in a mouse model of Buruli ulcer infection without relapse up to 19 weeks posttreatment. Clinical use of Q203 may… read more here.
Keywords: q203; toward single; single dose; buruli ulcer ... See more keywords